Trial Profile
A Phase 1 Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Ipilimumab in Chinese Subjects With Select Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Jul 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Carcinoma; Malignant melanoma; Nasopharyngeal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 01 Apr 2021 According to Results published in the Oncologist, a new cohort of nine patients was treated at 10 mg/kg (this would have been increased to 18 patients if DLTs were experienced by three or more patients at 3 mg/kg).
- 19 Feb 2020 Status changed from active, no longer recruiting to completed.
- 01 Apr 2019 Status changed from recruiting to active, no longer recruiting.